development aspects – Page 2

Gritstone Bio Files for Chapter 11 Bankruptcy, Seeks Strategic Alternatives to Preserve Clinical Research

7 months ago talkbio0Tagged Chapter 11, Clinical Research, Communicable Diseases, development aspects, Gritstone Bio, Neoplasms, strategic alternatives, Vaccines

Gritstone Bio, Chapter 11 bankruptcy, strategic alternatives, clinical research, vaccine development, oncology, infectious diseases

BIOSECURE Act: Navigating Industry Implications and Future Directions

7 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience

Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul

7 months ago talkbio0Tagged Biotechnology, development aspects, Drug Industry, Financial cost, Moderna, R&D, research

Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.

Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3

8 months ago talkbio0Tagged Bacterial Infections, development aspects, Phase 3 program, pneumococcal conjugate, Vaccines, VAX-31, Vaxcyte

Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases

Pfizer and Valneva Announce Positive Phase 2 Results for Lyme Disease Vaccine Candidate VLA15

8 months ago talkbio0Tagged development aspects, Lyme Disease, Pfizer, Tick-Borne Diseases, Vaccines, Valneva, VLA15

Lyme disease, VLA15, Pfizer, Valneva, vaccine development, tick-borne diseases

Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results

8 months ago talkbio0Tagged development aspects, Invasive Streptococcus pneumoniae disease, Phase 3 trials, Pneumococcal vaccine, Vaccines, VAX-31, Vaxcyte

Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development

UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development

8 months ago talkbio0Tagged California, development aspects, Gary Michelson, Immunology, Immunotherapy, research, Ucla, Vaccines

UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy